CO5070658A1 - Agentes terapeuticos utiles para el tratamiento y prevencion de enfermedades cardio vasculares en mujeres posmenopausi- cas - Google Patents

Agentes terapeuticos utiles para el tratamiento y prevencion de enfermedades cardio vasculares en mujeres posmenopausi- cas

Info

Publication number
CO5070658A1
CO5070658A1 CO97051289A CO97051289A CO5070658A1 CO 5070658 A1 CO5070658 A1 CO 5070658A1 CO 97051289 A CO97051289 A CO 97051289A CO 97051289 A CO97051289 A CO 97051289A CO 5070658 A1 CO5070658 A1 CO 5070658A1
Authority
CO
Colombia
Prior art keywords
women
posmenopausian
prevention
treatment
therapeutic agents
Prior art date
Application number
CO97051289A
Other languages
English (en)
Inventor
Jeremy N Bradbeer
Maxine Gowen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5070658A1 publication Critical patent/CO5070658A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para tratar y prevenir la enfermedad cardiovascular posmenopáusica en mujeres, que comprende administrar a una paciente necesitada de ello, una cantidad eficaz de un compuesto de fórmula I.Un uso según la reivindicación 4, en el que el compuesto de fórmula I es (E)-1-[2-[4-[1-(4-yodofenil )-2-fenil-1-butenil ] fenoxi ] pirrolidina.
CO97051289A 1996-09-06 1997-09-04 Agentes terapeuticos utiles para el tratamiento y prevencion de enfermedades cardio vasculares en mujeres posmenopausi- cas CO5070658A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24

Publications (1)

Publication Number Publication Date
CO5070658A1 true CO5070658A1 (es) 2001-08-28

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
CO97051289A CO5070658A1 (es) 1996-09-06 1997-09-04 Agentes terapeuticos utiles para el tratamiento y prevencion de enfermedades cardio vasculares en mujeres posmenopausi- cas
CO97051287A CO4920218A1 (es) 1996-09-06 1997-09-04 Agentes terapeuticos con base en idoxifeno, utiles en el tratamiento de la osteoporosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO97051287A CO4920218A1 (es) 1996-09-06 1997-09-04 Agentes terapeuticos con base en idoxifeno, utiles en el tratamiento de la osteoporosis

Country Status (16)

Country Link
EP (2) EP0929216A4 (es)
JP (2) JP2002515047A (es)
KR (2) KR20000068473A (es)
CN (2) CN1236313A (es)
AR (1) AR008155A1 (es)
AU (2) AU4247397A (es)
BR (2) BR9711676A (es)
CA (2) CA2264943A1 (es)
CO (2) CO5070658A1 (es)
CZ (1) CZ76699A3 (es)
IL (1) IL128645A0 (es)
NO (2) NO991096L (es)
PL (2) PL332038A1 (es)
TR (2) TR199900504T2 (es)
TW (1) TW411273B (es)
WO (2) WO1998009519A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (en) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260066B1 (en) * 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
HUT71244A (en) * 1992-09-15 1995-11-28 Merrell Dow Pharma Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
NO991097L (no) 1999-03-05
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
WO1998009519A1 (en) 1998-03-12
CN1236299A (zh) 1999-11-24
CZ76699A3 (cs) 1999-08-11
WO1998009619A1 (en) 1998-03-12
NO991096D0 (no) 1999-03-05
TW411273B (en) 2000-11-11
JP2002515046A (ja) 2002-05-21
CN1236313A (zh) 1999-11-24
CO4920218A1 (es) 2000-05-29
CA2264943A1 (en) 1998-03-12
PL332038A1 (en) 1999-08-16
TR199900504T2 (xx) 1999-06-21
EP0929216A4 (en) 2001-04-04
EP0927029A4 (en) 2001-06-13
CA2264775A1 (en) 1998-03-12
AR008155A1 (es) 1999-12-09
IL128645A0 (en) 2000-01-31
PL332278A1 (en) 1999-08-30
KR20000068473A (ko) 2000-11-25
BR9711676A (pt) 1999-08-24
NO991096L (no) 1999-03-05
EP0929216A1 (en) 1999-07-21
TR199900506T2 (xx) 1999-07-21
EP0927029A1 (en) 1999-07-07
JP2002515047A (ja) 2002-05-21
NO991097D0 (no) 1999-03-05
KR20000068472A (ko) 2000-11-25
AU4247397A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
ATE241378T1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
CA2289717A1 (en) Novel therapy for constipation
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
SE9404196D0 (sv) New antithrombotic formulation
AR004676A1 (es) Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
DE69327263D1 (de) Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose
YU32196A (sh) Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića
ES2171889T3 (es) Agente que reduce el colesterol en suero.
ES2157960T3 (es) Procedimiento para aumentar la libido en mujeres postmenopausicas.
ES2161238T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para inhibir la angiogenesis y enfermedades angiogenicas.
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CO5070658A1 (es) Agentes terapeuticos utiles para el tratamiento y prevencion de enfermedades cardio vasculares en mujeres posmenopausi- cas
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
DE69904465D1 (de) Therapie von depressionen
EE04658B1 (et) Pridasinooni derivaadi uus kasutusv?imalus
FI950403A0 (fi) Neurosuojaavia yhdisteitä
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
CO4940413A1 (es) Nuevos metodos